| Target Price | CN¥23.26 |
| Price | CN¥16.22 |
| Potential |
43.38%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Shanghai Pharmaceuticals-h 2027 .
The average Shanghai Pharmaceuticals-h target price is CN¥23.26.
This is
43.38%
register free of charge
CN¥27.17
67.53%
register free of charge
CN¥12.32
24.03%
register free of charge
|
|
| A rating was issued by 11 analysts: 7 Analysts recommend Shanghai Pharmaceuticals-h to buy, 3 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Shanghai Pharmaceuticals-h stock has an average upside potential 2027 of
43.38%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion CN¥ | 283.58 | 299.66 |
| 3.03% | 5.67% | |
| EBITDA Margin | 3.74% | 4.48% |
| 6.03% | 19.90% | |
| Net Margin | 2.02% | 1.82% |
| 22.05% | 9.84% |
10 Analysts have issued a sales forecast Shanghai Pharmaceuticals-h 2026 . The average Shanghai Pharmaceuticals-h sales estimate is
This results in the following potential growth metrics:
10 Shanghai Pharmaceuticals-h Analysts have issued a net profit forecast 2026. The average Shanghai Pharmaceuticals-h net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share CN¥ | 1.54 | 1.47 |
| 25.20% | 4.55% | |
| P/E | 11.02 | |
| EV/Sales | 0.23 |
10 Analysts have issued a Shanghai Pharmaceuticals-h forecast for earnings per share. The average Shanghai Pharmaceuticals-h EPS is
This results in the following potential growth metrics and future valuations:
Shanghai Pharmaceuticals-h...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


